Multi‐Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202402546 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Helena Freire Haddad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA. Hauptthemen laut MEDLINE: Nanofibers, Immunotherapy, Peptides, Inflammation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Science Foundation, NIH HHS.
Abstract (Originalsprache)
The anaphylatoxins C3a and C5a are products of the complement cascade that play important and interrelated roles in health and disease. Both are potential targets for anti‐inflammatory active immunotherapies in which a patient's own immune system is stimulated to produce therapeutic immune responses against problematic self‐molecules. However, the complex and time‐dependent interrelations between the two molecules make dual targeting challenging. To investigate a dual‐target active immunotherapy against C3a and C5a and to systematically study the effect of varied degrees of responses against both targets, the study employed self‐assembled peptide immunogens capable of displaying a broad range of epitope compositions and Design‐of‐Experiments (DoE) approaches. Peptide nanofibers contained B‐cell epitopes of C3a and C5a in defined quantities, and intranasal immunization raised systemic and mucosal immunity against each target. In a lipopolysaccharide‐induced model of sepsis, increasing anti‐C5a responses are protective, whereas increasing anti‐C3a responses are detrimental, and survival rates are negatively correlated with anti‐C3a/anti‐C5a IgG titer ratio. This work highlights the interplay between the two molecules by making use of a modular, defined, and easily adjusted biomaterial‐based active immunotherapy platform.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Duke University, Durham, NC, 27708, USA.
ORCID-Profile: Joel H Collier
Förderung
- NIAID NIH HHS
- National Science Foundation
- NIH HHS
- Duke University
- National Institutes of Health
Zitieren
APA
Freire Haddad, H., Roe, E. F., Xie Fu, V., Curvino, E. J., & Collier, J. H. (2025). Multi‐Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402546
Vancouver
Freire Haddad H, Roe EF, Xie Fu V, Curvino EJ, Collier JH. Multi‐Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202402546
BibTeX
@article{FreireHaddad2025,
author = {Freire Haddad, Helena and Roe, Emily F and Xie Fu, Vinicius and Curvino, Elizabeth J and Collier, Joel H},
title = {Multi‐Target Peptide Nanofiber Immunotherapy Diminishes Complement Anaphylatoxin Activity in Acute Inflammation},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202402546}
}
EUVIMED